Obstetrics & Gynecology Doctors in Avondale, AZ Accepting Medicare

7 Obstetrics & Gynecology doctors found. Showing 1 - 7

Justice Huy Duc Tran, M.D. Obstetrics & Gynecology Medicare: Medicare Enrolled Practice Location: 3400 N Dysart Rd, Building F, Ste 121 & 123, Avondale, AZ 85392 Phone: 623-792-8397    Fax: 623-544-5187

Shashank Shekhar Srivastava, M.D. Obstetrics & Gynecology Medicare: Accepting Medicare Assignments Practice Location: 10815 W Mcdowell Rd Ste 301, Avondale, AZ 85392 Phone: 623-512-4466    Fax: 623-512-4460

Mr. Randall James Reid, MD Obstetrics & Gynecology Medicare: Accepting Medicare Assignments Practice Location: 10815 W. Mcdowell Rd, Ste 301, Avondale, AZ 85392 Phone: 623-433-0106    Fax: 623-433-0108

Liani Kelly Mccline, PA-C Obstetrics & Gynecology Medicare: Accepting Medicare Assignments Practice Location: 10815 W Mcdowell Rd Ste 301, Avondale, AZ 85392 Phone: 623-535-0740    Fax: 623-512-4460

George Davidson, MD Obstetrics & Gynecology Medicare: Accepting Medicare Assignments Practice Location: 10815 W Mcdowell Rd Ste 301, Avondale, AZ 85392 Phone: 623-535-0740    Fax: 623-535-0741

Shahrzad Borhan-manesh, MD Obstetrics & Gynecology Medicare: Accepting Medicare Assignments Practice Location: 3400 N Dysart Rd, Ste 121, Avondale, AZ 85392 Phone: 623-583-3001    Fax: 623-583-3007

Dr. Miles Wayne Howard, MD Obstetrics & Gynecology Medicare: Accepting Medicare Assignments Practice Location: 10815 W Mcdowell Rd Ste 301, Avondale, AZ 85392 Phone: 623-535-0740    Fax: 623-535-0741

News Archive

Merrimack announces results from MM-302 Phase I trial on advanced HER2 positive breast cancer

Merrimack Pharmaceuticals, Inc. today announced Phase I clinical trial results for MM-302, the company's novel agent for the treatment of advanced HER2 positive (HER2+ or ErbB2+) breast cancer.

Nanoparticle-delivered suicide gene therapy effectively reduces ovarian tumor burden in mice

Nanoparticle delivery of diphtheria toxin-encoding DNA that expresses selectively in ovarian cancer cells reduced the burden of ovarian tumors in mice, and researchers expect that this therapy could be tested in humans with advanced ovarian cancer within 18 to 24 months, according to a report in Cancer Research. If additional tests are successful, these finding could lead to a new treatment for ovarian cancer, which now causes more than 15,000 deaths each year in the United States. Because it is usually diagnosed at a relatively late stage, ovarian cancer is one of the most deadly forms of the disease.

BMI history points to diabetes risk

Changes in body mass index across a person's life can help to gauge the likelihood of undiagnosed diabetes, say researchers.

Insulin pumps better than injections for glycaemic control in Type 2 diabetes

Patients with Type 2 diabetes achieve better glycaemic control with insulin pumps than multiple insulin injections, show the findings of the OpT2mise randomised trial.

Read more Medical News

› Verified 3 days ago